AEterna Zentaris (AEZS)
(Delayed Data from NSDQ)
$5.35 USD
-0.05 (-0.93%)
Updated Jul 26, 2024 02:51 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
AEterna Zentaris Inc. [AEZS]
Reports for Purchase
Showing records 41 - 60 ( 168 total )
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Fundamentally Strong with Potential to Grow; Reiterate Buy
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Building an Endocrinology Franchise One Relationship at a Time; Reiterate Buy
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Macrilen Development Pathway Clear; Upgrading to Buy; Price Target $1.25
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Strong Estrogel Launch to Spell Commercial Success; Maintain Neutral
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
2015 Preview: Industry Signals Imply Continued Growth
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
CRL Jeopardizes Macrilen Commercialization; Downgrade to Neutral
Provider: H.C. WAINWRIGHT & CO., INC.
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
3Q13 Results; Strong Late Stage Pipeline; Catalysts Coming; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
NDA Filed for Macimorelin Acetate for AGHD; Nice Increment for Company
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
2Q13 Results; Visibility on Programs Continues to Increase
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
108 Phase III Begins as Expected; Target Reduced to $5.40
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
1Q13 Results; Late Stage Focus and Imminent NDA
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Ergomed to Provide Important ''108 Phase III Support
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J